PO.BCS02.06 · 生物信息与计算
ProteoBridge:通过基于组织学的蛋白质预测衔接跳过的切片
ProteoBridge: Bridging skipped sections via histology-based protein prediction
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:空间多模态平台的进展已实现对组织内各类分子和形态学特征的高分辨率作图。蛋白质影响细胞表型和肿瘤微环境的组织结构,其丰度和分布模式在相邻连续切片中高度相关。诸如Singular Genomics G4X等空间多模态平台能够从同一组织切片捕获H&E染色图像、多重蛋白质表达和靶向RNA转录组,如今为三维(3D)空间多模态分析和3D肿瘤微环境建模奠定了基础。然而,跨整个组织切片堆栈进行全面的多重蛋白质成像成本高昂、劳动密集且不切实际,导致蛋白质组采样稀疏,限制了准确的3D重建。方法:我们开发了ProteoBridge,一个基于深度学习的框架,用于预测跨连续组织切片的蛋白质表达模式,从而使3D分子建模所需的蛋白质组信息更加密集。对于每个组织堆栈,模型在第一张切片上进行训练,该切片包含H&E、多重蛋白质图像和RNA转录组。输入包括H&E图块和RNA转录组数据,而输出为同一视野的多通道蛋白质图谱。靶向RNA转录组与H&E染色形态学的结合有助于界定细胞类型和状态,使模型能够基于转录程序学习形态学与蛋白质之间的关系。训练重点在于降低跨蛋白质通道的平均绝对误差,以建立未测量切片的组织学-蛋白质对应关系。结果:我们在含多张已分析切片的组织堆栈上评估了ProteoBridge,评估了预测的蛋白质图谱与实测蛋白质图谱之间的图像级相似性。在单切片监督下,ProteoBridge准确再现了标志物强度并保持了跨平面一致性,同时捕获了蛋白质的强度值和空间组织。通过填补被跳过的平面,ProteoBridge生成了更连续的肿瘤蛋白质组3D表征,适用于下游3D分子建模和可视化。结论:ProteoBridge仅需对堆栈中其余切片进行常规H&E染色,即可推断跨连续平面的蛋白质强度,从而降低成本和周转时间,同时扩展有效的蛋白质组覆盖范围。利用G4X平台的多模态数据并将蛋白质预测扩展到未测量区域,可实现肿瘤蛋白质组具成本效益的3D重建,增强对肿瘤微环境及其异质性的分子建模。生成式AI仅协助了本摘要的语言润色。作者对科学内容和结论负全部责任,并已审阅和批准最终版本。
查看英文原文 English abstract
Background: The progress of spatial multimodal platforms has enabled high-resolution mapping of various types of molecular and morphological characteristics within a tissue. Proteins influence cellular phenotypes and the organization of the tumor microenvironment, with their abundance and patterns highly correlated in adjacent serial sections. Spatial Multimodal platforms such as Singular Genomics G4X, which capture H&E-stained images, multiplexed protein expression, and targeted RNA transcriptomics from the same tissue slide, now create a foundation for three-dimensional (3D) spatial multimodal profiling and 3D tumor microenvironment modeling. However, comprehensive multiplex protein imaging across entire tissue stacks is costly, labor-intensive, and impractical, leading to sparse proteomic sampling that limits accurate 3D reconstruction.Methods: We developed ProteoBridge, a deep learning-based framework that predicts protein expression patterns across serial tissue sections to densify the proteomic information needed for 3D molecular modeling. For each tissue stack, the model was trained on the first section, which contains H&E, multiplex protein images, and RNA transcriptomics. The inputs include H&E tiles and RNA transcriptome data, while the outputs are multi-channel protein maps for the same field of view. The combination of targeted RNA transcriptomics and H&E stained morphology helps define cell types and states, allowing the model to learn morphology-to-protein relationships based on transcriptional programs. The training focused on reducing mean absolute error across protein channels to establish histology-protein correspondences for unmeasured sections.Results: We evaluated ProteoBridge on tissue stacks with multiple profiled sections. Image-level similarity between predicted and measured protein maps was assessed. Using single-slide supervision, ProteoBridge accurately reproduced marker intensities and preserved cross-plane consistency, capturing both intensity values and spatial organization of proteins.. By filling in skipped planes, ProteoBridge generates a more continuous 3D representation of the tumor proteome suitable for downstream 3D molecular modeling and visualization.Conclusion: ProteoBridge requires only routine H&E staining on the remaining sections in a stack to infer protein intensities across serial planes, reducing cost and turnaround time while expanding effective proteomic coverage. Using the G4X platform's multimodal data and extending protein predictions to unmeasured areas allows for cost-effective 3D reconstruction of the tumor proteome, enhancing molecular modeling of the tumor microenvironment and its heterogeneity.Generative AI assisted only with language editing of this abstract. The authors retain sole responsibility for the scientific content and conclusions, having reviewed and approved the final version.
利益披露 Disclosure
M. Kim, None..
S. Park, None..
S. Chung, None..
I. Jang, None..
J. R. Clemenceau, None..
S. Im, None..
E. Sha, None.
H. Choi,
LG AI Research Employment.
S. Lee,
LG AI Research Employment.
J. Jang,
LG AI Research Employment.
S. C. Wang, None.
T. Hwang,
Kure.ai therapeutics Other Business Ownership, T.H.H. is a co-founder of Kure.ai therapeutics.
Kure.s Other Business Ownership, T.H.H. is a co-founder of Kure.s.
IQVIA Other, T.H.H. has received consulting fees from IQVIA.